41
Egypt-based Eva Pharma has signed a deal with Gilead Sciences for manufacturing and sale of remdesivir, which has shown promising results in treating coronavirus during two phases of initial trials.
The company has the right to manufacture and distribute the coronavirus drug in 127 countries, Riad Armanious — chief executive officer, Eva Pharma.
The decision was taken after the company got emergency use authorisation in the U.S. Remdesivir had shown promising results during two phases of trials, with the recent one by the U.S. National Institute of Allergy and Infectious Diseases.
The company has a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly.
